NO326659B1 - Fremgangsmate ved bestemmelse av transformerende effekt hos et mulig transformerende middel ved bestemmelse av apoptoseinduserende aktivitet - Google Patents

Fremgangsmate ved bestemmelse av transformerende effekt hos et mulig transformerende middel ved bestemmelse av apoptoseinduserende aktivitet Download PDF

Info

Publication number
NO326659B1
NO326659B1 NO20000736A NO20000736A NO326659B1 NO 326659 B1 NO326659 B1 NO 326659B1 NO 20000736 A NO20000736 A NO 20000736A NO 20000736 A NO20000736 A NO 20000736A NO 326659 B1 NO326659 B1 NO 326659B1
Authority
NO
Norway
Prior art keywords
apoptin
cells
apoptosis
cancer
normal
Prior art date
Application number
NO20000736A
Other languages
English (en)
Norwegian (no)
Other versions
NO20000736L (no
NO20000736D0 (no
Inventor
Mathieu Hubertus Maria Noteborn
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd Bv filed Critical Leadd Bv
Publication of NO20000736D0 publication Critical patent/NO20000736D0/no
Publication of NO20000736L publication Critical patent/NO20000736L/no
Publication of NO326659B1 publication Critical patent/NO326659B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Measurement Of Current Or Voltage (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
NO20000736A 1997-08-12 2000-02-14 Fremgangsmate ved bestemmelse av transformerende effekt hos et mulig transformerende middel ved bestemmelse av apoptoseinduserende aktivitet NO326659B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97202501 1997-08-12
PCT/NL1998/000457 WO1999008108A1 (en) 1997-08-12 1998-08-11 Determining the transforming capability of agents

Publications (3)

Publication Number Publication Date
NO20000736D0 NO20000736D0 (no) 2000-02-14
NO20000736L NO20000736L (no) 2000-04-11
NO326659B1 true NO326659B1 (no) 2009-01-26

Family

ID=8228640

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000736A NO326659B1 (no) 1997-08-12 2000-02-14 Fremgangsmate ved bestemmelse av transformerende effekt hos et mulig transformerende middel ved bestemmelse av apoptoseinduserende aktivitet

Country Status (16)

Country Link
US (1) US6528247B1 (cs)
EP (1) EP1004021B1 (cs)
JP (1) JP4287588B2 (cs)
KR (1) KR20010022812A (cs)
AT (1) ATE283478T1 (cs)
AU (1) AU756587B2 (cs)
BR (1) BR9811163A (cs)
CA (1) CA2301401C (cs)
CZ (1) CZ299874B6 (cs)
DE (1) DE69827805T2 (cs)
NO (1) NO326659B1 (cs)
NZ (1) NZ502800A (cs)
PL (1) PL196605B1 (cs)
RU (1) RU2214598C2 (cs)
SK (1) SK286235B6 (cs)
WO (1) WO1999008108A1 (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW514581B (en) * 1999-09-02 2002-12-21 Ciba Sc Holding Ag A method of protecting wood against light-induced degradation by treatment with an impregnation which penetrates the surface of the wood
CA2383784A1 (en) * 1999-09-02 2001-03-08 Leadd B.V. Apoptin-associating protein
WO2001042461A2 (en) 1999-12-10 2001-06-14 Leadd B.V. Apoptin-associating protein
EP1199363A1 (en) 2000-10-20 2002-04-24 Leadd B.V. Phosphorylation modifications of apoptin
EP1377667B1 (en) * 2001-03-30 2008-11-19 Leadd B.V. Fusion proteins for specific treatment of cancer and auto-immune diseases
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
AU2003904086A0 (en) 2003-08-04 2003-08-21 Cochlear Limited Implant battery short circuit protection
RU2325200C2 (ru) * 2006-02-20 2008-05-27 Федеральное государственное унитарное предприятие "НПО Астрофизика" Способ лазерного подавления роста и элиминации злокачественных образований
RU2340349C2 (ru) * 2006-08-10 2008-12-10 Геннадий Петрович Македонов Способ стимулирования апоптоза
DK2658872T3 (da) 2010-12-27 2020-10-12 Apo T B V Polypeptid, der binder aberrerende celler og inducerer apoptose
WO2013048243A1 (en) 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
EP2802356A1 (en) 2012-01-13 2014-11-19 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
HU215778B (hu) * 1991-01-15 1999-02-01 Oy Biotie Therapies Ltd. Eljárás szindekántartalom kimutatására biológiai anyagokban, így szövetekben és testnedvekben, a sejtek rosszindulatú transzformációinak jelzésére
EP0878546A1 (en) 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
CZ82692A3 (en) * 1992-03-19 1994-02-16 Prirodovedecka Fakulta Uk Method of testing cyctotoxicity and genotoxicity of chemicals
DE69628431T2 (de) * 1995-06-07 2004-05-06 Leadd B.V. Verwendungen von apoptin
JPH1015250A (ja) 1996-06-28 1998-01-20 Sega Enterp Ltd ゲーム装置
EP0921192A1 (en) * 1997-12-03 1999-06-09 Leadd B.V. Molecules interacting with apoptin
EP0927757A1 (en) * 1997-12-03 1999-07-07 Leadd B.V. Methods and means for inducing apoptosis by interfering with Bip-like proteins

Also Published As

Publication number Publication date
PL338683A1 (en) 2000-11-20
WO1999008108A1 (en) 1999-02-18
CZ2000479A3 (cs) 2000-06-14
RU2214598C2 (ru) 2003-10-20
KR20010022812A (ko) 2001-03-26
AU8752998A (en) 1999-03-01
NO20000736L (no) 2000-04-11
JP4287588B2 (ja) 2009-07-01
CA2301401C (en) 2008-10-21
AU756587B2 (en) 2003-01-16
NO20000736D0 (no) 2000-02-14
PL196605B1 (pl) 2008-01-31
CZ299874B6 (cs) 2008-12-17
DE69827805T2 (de) 2005-12-15
SK286235B6 (sk) 2008-06-06
BR9811163A (pt) 2000-07-25
EP1004021B1 (en) 2004-11-24
NZ502800A (en) 2002-10-25
EP1004021A1 (en) 2000-05-31
JP2001512829A (ja) 2001-08-28
CA2301401A1 (en) 1999-02-18
SK1902000A3 (en) 2000-11-07
US6528247B1 (en) 2003-03-04
ATE283478T1 (de) 2004-12-15
DE69827805D1 (de) 2004-12-30

Similar Documents

Publication Publication Date Title
Robanus-Maandag et al. p107 is a suppressor of retinoblastoma development in pRb-deficient mice
Shinoura et al. Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor gene therapy
Coates et al. Mammalian prohibitin proteins respond to mitochondrial stress and decrease during cellular senescence
Hayward et al. Establishment and characterization of an immortalized but non-transformed human prostate epithelial cell line: BPH-1
Feddersen et al. In vivo viability of postmitotic Purkinje neurons requires pRb family member function
Singh et al. The BH3 only Bcl-2 family member BNIP3 regulates cellular proliferation
JP4287588B2 (ja) 作用因子の形質転換能力定量
Hsu et al. Dysfunctional spermatogenesis in transgenic mice overexpressing bHLH-Zip transcription factor, Spz1
KR20010006460A (ko) 세포자멸사 유도 단백질 브이피2 및/또는 아폽틴을 발현시키는 유전자 전달 운반자
Peng et al. The leucine zipper putative tumor suppressor 2 protein LZTS2 regulates kidney development
Pinkert et al. Tumorigenesis in transgenic mice by a nuclear transport-defective SV40 large T-antigen gene
Hariri et al. Degenerated hair follicle cells and partial loss of sebaceous and eccrine glands in a familial case of axenfeld-rieger syndrome: An emerging role for the FOXC1/NFATC1 genetic axis
MXPA00001410A (en) Determining the transforming capability of agents
US20110047631A1 (en) Heat shock protein deficiencies as model systems for brain pathology and cancer
Zhang et al. Experiment and observation on invasion of brain glioma in vivo
EP1304371A1 (en) Cds1 GENE-KNOCKOUT CELLS AND MOUSE AND UTILIZATION THEREOF
Regeling et al. Mice defective in p53 nuclear localization signal 1 exhibit exencephaly
Palata Investigating the role of IRE1 in brain regeneration using a larval zebrafish model
Kuwajima et al. Synaptopodin KO rat for assessing the dendritic spine apparatus and axonal cisternal organelle in synaptic plasticity, development, and behavior
Sun Characterization of Rb1 function in the absence of normal E2F binding
Hayward et al. Rescue and isolation of Rb-deficient prostate epithelium by tissue recombination
Morgenbesser Differential function of Myc-family oncoproteins in proliferation and differentiation in a well-defined cell type, in vivo
US7816089B2 (en) Methods for diagnosing and treating pediatric neoplasms
Leung Immortalization of human ovarian surface epithelium with a temperature sensitive immortalization agent
NAKANISHI et al. Abstracts THE 40TH MEMORIAL SCIENTIFIC MEETING OF THE JAPAN SOCIETY OF HISTOCHEMISTRY AND CYTOCHEMISTRY

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees